FindTrial
Sign In

Safety and efficacy of switching to DTG plus 3TC regimen from a LPV/ R +TDF+3TC based second line regimen: a real world study from China with extensive experience in the use of LPV/r and TDF regimens (abridged edition)

Safety and efficacy of switching to DTG plus 3TC regimen from a LPV/ R +TDF+3TC based second line regimen: a real world study from China with extensive experience in the use of LPV/r and TDF regimens (abridged edition)

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034717
Enrollment
Unknown
Registered
2020-07-16
Start date
2020-07-15
Completion date
Unknown
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

case series:DTG+3TC

Sponsors

Zhengzhou Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients with age >= 18 years old and of any gender who are receiving antiviral treatment in Henan Province free antiviral treatment library; 2. The patients who used the first-line antiviral drugs (AZT / TDF / 3TC / NVP / EFV) in the past have been replaced with TDF + 3TC + LPV / R >= 12 months, and the HIV viral load within 6 months is <= 50 copies / ml.

Exclusion criteria

Exclusion criteria: 1. Patients with malignant tumor; 2. Patients with pregnancy; 3. Patients who could not complete the 48 week follow-up; 4. Patients with HIV integrase inhibitor treatment history or drug resistance history; 5. Patients with HBV infection. 6. Patients who are not suitable for this project.

Design outcomes

Primary

MeasureTime frame
HIV virus load;ALP;CTX;P1NP;VitD3;PTH;eGFR;S-cyc;TG;TC;HDL;LDL;—

Countries

China

Contacts

Public ContactZhao Qingxia

Zhengzhou Sixth People's Hospital

zhqx666@163.com+86 13623816821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026